Oral Aminoglycoside Recommendations
Paromomycin (aminosidine) is the only oral aminoglycoside used clinically, with specific dosing of 25-35 mg/kg/day divided twice daily for 5-10 days for intestinal amoebiasis, topical formulations (15% paromomycin ± 0.5% gentamicin cream) applied once daily for 20 days for cutaneous leishmaniasis, and oral neomycin (not paromomycin) for bowel decontamination.
Key Clinical Context
Aminoglycosides are polar drugs with poor gastrointestinal absorption, making them ineffective systemically when given orally 1. This property is exploited therapeutically for luminal intestinal infections and bowel decontamination, where the drug remains in the GI tract.
Specific Indications and Dosing
Intestinal Amoebiasis
- Paromomycin (aminosidine): The evidence supports twice-daily dosing for 5 days 2
- In the Kenyan study, aminosidine achieved 98% parasitological cure at end of treatment with only 6% relapse rate 2
- Anatomical cure (ulcer healing) reached 88.5% with excellent to good tolerance 2
- The combination with nimorazole (NA) showed even better results (100% parasitological cure, 3% relapse, 97.8% anatomical cure), though this may not be readily available 2
Practical dosing: Standard aminosidine dosing for amoebiasis is typically 25-35 mg/kg/day divided into two doses for 5-10 days, though the study used twice-daily dosing without specifying exact mg/kg.
Cutaneous Leishmaniasis
Topical paromomycin is the oral/non-invasive aminoglycoside option 3:
- 15% paromomycin + 12% methylbenzethonium chloride (MBCL) ointment: Apply twice daily for 10 days 3
- 15% paromomycin + 0.5% gentamicin cream: Apply once daily for 20 days 3
- The capsule formulation requires compounding by pharmacy (off-label use) 3
Critical caveat: Higher response rates occur with L. major than L. tropica 3. Systemic paromomycin (14 mg/kg/day IM for 20 days) showed poor efficacy against L. braziliensis in American cutaneous leishmaniasis, healing only 10 of 17 lesions versus 15 of 17 with sodium stibogluconate 4.
Common pitfall: Local irritation from MBCL may cause patients to discontinue therapy 3. Consider the paromomycin-gentamicin formulation as an alternative.
Bowel Decontamination
Neomycin (not paromomycin) is the standard oral aminoglycoside for selective bowel decontamination, though this was not specifically addressed in the provided evidence. Standard practice uses neomycin 1 gram orally every 4-6 hours, often combined with other agents like erythromycin for preoperative bowel preparation.
Important Clinical Considerations
Why Oral Administration Works for These Indications
The poor GI absorption of aminoglycosides 1 means oral paromomycin:
- Remains in the intestinal lumen for direct antiparasitic effect against E. histolytica
- Achieves high local concentrations without systemic toxicity
- Does not require renal function monitoring when used orally for luminal infections
Toxicity Monitoring
For topical use: Monitor for local erythema and mild pain, which are commonly noted 3. Systemic absorption is minimal, so nephrotoxicity and ototoxicity are not concerns with topical application.
For oral luminal use: Systemic absorption is minimal, but prolonged use could theoretically cause some absorption. The Kenyan study showed excellent tolerance 2.
Availability Issues
Paromomycin capsules are FDA-approved for other indications; compounding for topical leishmaniasis ointment constitutes off-label use 3. The expanded-access IND protocol for the paromomycin-gentamicin cream is currently limited to US military healthcare beneficiaries 3.